pharma · Major Depressive Disorder · Primary Erythromelalgia · XENE
Xenon Pharmaceuticals
Xenon Pharmaceuticals clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 3650 Gilmore Way, Burnaby, BC V5G 4W8, CA
- Employees
- 397
- Programs
- 22
- Drugs
- 2
- Patents
- 106
Xenon Pharmaceuticals projects
10 ClinicalTrials.gov programs sponsored by Xenon Pharmaceuticals.
Xenon Pharmaceuticals has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Azetukalner
Xenon Pharmaceuticals
Bipolar Depression
1 trial -
Azetukalner
Xenon Pharmaceuticals
Major Depressive Disorder
3 trials -
Azetukalner
Xenon Pharmaceuticals
Bipolar Disorder
1 trial -
Placebo, XPF-010
Xenon Pharmaceuticals
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
1 trial -
XEN1101
Xenon Pharmaceuticals
Primary Generalized Tonic-Clonic Seizures
1 trial -
XEN1101
Xenon Pharmaceuticals
Focal Epilepsy
2 trials -
XEN1101
Xenon Pharmaceuticals
Focal Onset Seizures
2 trials -
XEN496
Xenon Pharmaceuticals
Epilepsy
2 trials -
XPF-010
Xenon Pharmaceuticals
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
1 trial -
XPF-010, Placebo to match XPF-010
Xenon Pharmaceuticals
Major Depressive Disorder
1 trial
Frequently asked questions
How many clinical projects does Xenon Pharmaceuticals have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.